Compare AGM & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGM | PGEN |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | N/A | 2013 |
| Metric | AGM | PGEN |
|---|---|---|
| Price | $158.14 | $3.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $215.00 | $7.67 |
| AVG Volume (30 Days) | 104.3K | ★ 4.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.02% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $22.27 | $342.78 |
| Revenue Next Year | $4.06 | $478.46 |
| P/E Ratio | $9.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $146.69 | $1.11 |
| 52 Week High | $210.64 | $5.47 |
| Indicator | AGM | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 41.83 | 31.99 |
| Support Level | $156.98 | $2.99 |
| Resistance Level | $168.85 | $5.10 |
| Average True Range (ATR) | 6.07 | 0.36 |
| MACD | -1.09 | -0.14 |
| Stochastic Oscillator | 35.13 | 4.06 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven segments: Farm & Ranch, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.